Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of alcohol use disorder (AUD).
According to Clearmind, participant recruitment at leading sites—including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center—follows the positive topline results recently reported from the second cohort, which demonstrated continued safety and tolerability, building on the favorable outcomes from prior cohorts.
In a statement, Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “Building on the encouraging results from our first and second cohort, we are excited on progressing with the clinical trial at these prestigious institutions. The positive data we continue to receive from our clinical trial, reinforce CMND-100’s potential as a safe and well tolerated, non-hallucinogenic treatment option that addresses the critical unmet needs in alcohol use disorder, without requiring adjunct psychotherapy, making this treatment accessible and discrete. We remain committed to progressing this trial to bring innovative, safe and affordable solutions to patients in need.”
